Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukaemia: results from Cancer and Leukaemia Group B (CALGB 8461) - Byrd, JC; Mrozek, K; Dodge, RK (Blood, 2002)